NEW YORK (GenomeWeb) – Protea Biosciences today announced that it has entered into an agreement to buy the research services firm VivoPharm for cash and equity.

According to the firm's 8-K filed with the SEC on April 6, Protea will acquire all shares of Hershey, Pa.-based VivoPharm and its subsidiaries for $11.2 million, including $5.4 million in cash and $5.7 million in the form of 570,053 shares of new Series A stock. Upon completion of the deal, VivoPharm will operate as a business unit of Protea, the firm said in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.